Search

Your search keyword '"Graff‐Guerrero, Ariel"' showing total 1,152 results
Start Over Author "Graff‐Guerrero, Ariel"
1,152 results on '"Graff‐Guerrero, Ariel"'

153. Individual determinants of COVID-19 vaccine hesitancy

Author

Gerretsen, Philip, primary, Kim, Julia, additional, Caravaggio, Fernando, additional, Quilty, Lena, additional, Sanches, Marcos, additional, Wells, Samantha, additional, Brown, Eric E., additional, Agic, Branka, additional, Pollock, Bruce G., additional, and Graff-Guerrero, Ariel, additional

Published
2021
Full Text
View/download PDF

155. Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies

Author

Nakahara, Tomomi, primary, Tsugawa, Sakiko, additional, Noda, Yoshihiro, additional, Ueno, Fumihiko, additional, Honda, Shiori, additional, Kinjo, Megumi, additional, Segawa, Hikari, additional, Hondo, Nobuaki, additional, Mori, Yukino, additional, Watanabe, Honoka, additional, Nakahara, Kazuho, additional, Yoshida, Kazunari, additional, Wada, Masataka, additional, Tarumi, Ryosuke, additional, Iwata, Yusuke, additional, Plitman, Eric, additional, Moriguchi, Sho, additional, de la Fuente-Sandoval, Camilo, additional, Uchida, Hiroyuki, additional, Mimura, Masaru, additional, Graff-Guerrero, Ariel, additional, and Nakajima, Shinichiro, additional

Published
2021
Full Text
View/download PDF

163. Gamma‐aminobutyric acid (GABA) levels in the midcingulate cortex and clozapine response in patients with treatment‐resistant schizophrenia: A proton magnetic resonance spectroscopy (1H‐MRS) study.

Author

Ueno, Fumihiko, Nakajima, Shinichiro, Iwata, Yusuke, Honda, Shiori, Torres‐Carmona, Edgardo, Mar, Wanna, Tsugawa, Sakiko, Truong, Peter, Plitman, Eric, Noda, Yoshihiro, Mimura, Masaru, Sailasuta, Napapon, Mikkelsen, Mark, Edden, Richard A.E., De Luca, Vincenzo, Remington, Gary, Gerretsen, Philip, and Graff‐Guerrero, Ariel

Subjects
PROTON magnetic resonance spectroscopy, GABA, CLOZAPINE, PEOPLE with schizophrenia
Abstract

Background: Gamma‐Aminobutyric Acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system. GABAergic dysfunction has been implicated in the pathophysiology of schizophrenia. Clozapine, the only approved drug for treatment‐resistant schizophrenia (TRS), involves the GABAergic system as one of its targets. However, no studies have investigated the relationship between brain GABA levels, as measured by proton magnetic resonance spectroscopy (1H‐MRS), and clozapine response in patients with TRS. Methods: This study enrolled patients with TRS who did not respond to clozapine (ultra‐resistant schizophrenia: URS) and who responded to clozapine (non‐URS), patients with schizophrenia who responded to first‐line antipsychotics (first‐line responders: FLR), and healthy controls (HCs). We measured GABA levels in the midcingulate cortex (MCC) using 3T 1H‐MRS and compared these levels among the groups. The associations between GABA levels and symptom severity were also explored within the patient groups. Results: A total of 98 participants (URS: n = 22; non‐URS: n = 25; FLR: n = 16; HCs: n = 35) completed the study. We found overall group differences in MCC GABA levels (F(3,86) = 3.25, P = 0.04). Specifically, patients with URS showed higher GABA levels compared to those with non‐URS (F(1,52) = 8.40, P = 0.03, Cohen's d = 0.84). MCC GABA levels showed no associations with any of the symptom severity scores within each group or the entire patient group. Conclusion: Our study is the first to report elevated GABA levels in the MCC in patients with schizophrenia resistant to clozapine treatment compared with those responsive to clozapine. Longitudinal studies are required to evaluate if GABA levels are a suitable biomarker to predict clozapine resistance. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

166. Psychometric properties of Gaudiebility Scale (Modulators of Enjoyment) for Children and Adolescents (GSCA)

Author

Padrós-Blázquez, Ferran, Martinez-Medina, María P., Guàrdia Olmos, Joan, and Graff-Guerrero, Ariel

Subjects
Validación, Análisis Factorial Confirmatorio, Positive Affect, 1 - Filosofía y psicología::159.9 - Psicología [CDU], Psychology, Disfrute, Modulators, Enjoy, Moduladores, Confirmatory Factor Analysis, Afecto positivo, BF1-990, Validity
Abstract

The decrease in the ability to enjoy can be considered a risk factor or marker of mental disorders. Therefore, it can be useful to have a scale to quantify gaudiebility in children and adolescents. The objective of the present work was to build and analyze the psychometric properties of the Gaudiebility Scale for Children and Adolescents (GSCA). 1,264 primary, secondary and high school students responded to GSCA, Rosenberg’s selfesteem scale, Positive and Negative Affect schedule, Center of Epidemiological Studies of Depression scale. Through a confirmatory factor analysis using WLSMV (Weighted Least Square) estimation with a reparameterization with a value of δ = .05 and forcing a non-orthogonal factor structure was observed to 5 factors model (Enjoyment in Company, Self-efficacy versus boredom, Sense of humor, Imagination and Interest) related, results (χ2/df = 9.40; CFI = .931; TLI = .946) indicate that the modification indices did not present relevant values, so it would not be pertinent to propose any other alternative model. In addition, an appropriate internal reliability (Cronbach α = .794) was observed in the total scale and in the 5 subscales. Finally, an adequate evidence of validity was observed. It is concluded that GSCA seems appropriate to quantify gaudiebility levels in children and adolescents. La disminución de la capacidad de disfrute puede considerarse un factor de riesgo de trastornos mentales. Por ello, es de utilidad disponer de instrumentos válidos para evaluar la gaudibilidad en niños y adolescentes. El objetivo del presente trabajo fue construir y analizar las propiedades psicométricas de la Escala de Gaudibilidad para Niños y Adolescentes (EGNA). 1.264 estudiantes de primaria, secundaria y bachillerato respondieron a: EGNA, Escala de Autoestima de Rosenberg, Escalas Panas de afecto positivo y negativo para niños y adolescentes y la escala de Depresión del Centro de Estudios Epidemiológicos. Mediante un análisis factorial confirmatorio utilizando Weighted Least Square con una reparametrización con un valor de δ = .05 y forzando una estructura entre factores no ortogonal con el modelo de 5 factores (Disfrute en compañía, Autoeficacia frente al aburrimiento, Sentido del humor, Imaginación e interés) relacionados, los resultados (χ2/df = 9.40; CFI = .931;TLI = .946) indican que los índices de modificación no presentaron valores relevantes, de forma que no sería pertinente proponer ningún otro modelo alternativo. Además, se observó una consistencia interna adecuada (Cronbach α = .794) en la escala total y en los 5 factores. Finalmente se observaron adecuadas evidencias validez. Se concluye que la EGNA es adecuada para cuantificar los niveles de gaudibilidad en niños y adolescentes.

Published
2021

169. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study with [11C]-(+)-PHNO

Author

Graff-Guerrero, Ariel, Mamo, David, Shammi, C.M., Mizrahi, Romina, Marcon, Heidi, Barsoum, Penny, Rusjan, Pablo, Houle, Sylvain, Wilson, Alan A., and Kapur, Shitij

Subjects
Antipsychotic drugs -- Dosage and administration, Antipsychotic drugs -- Physiological aspects, Antipsychotic drugs -- Research, Dopamine receptors -- Physiological aspects, Dopamine receptors -- Research, PET imaging -- Research, Schizophrenia -- Care and treatment, Schizophrenia -- Research, Health, Psychology and mental health
Published
2009

170. Using Bayesian Modeling to Optimize Antipsychotic Dosage in Clinical Practice

Author

Ismail, Mohamed, primary, Straubinger, Thomas, additional, Uchida, Hiroyuki, additional, Graff-Guerrero, Ariel, additional, Nakajima, Shinichiro, additional, Suzuki, Takefumi, additional, Caravaggio, Fernando, additional, Gerretsen, Philip, additional, Mamo, David, additional, Mulsant, Benoit, additional, Pollock, Bruce, additional, and Bies, Robert, additional

Published
2021
Full Text
View/download PDF

171. Increased Regional Cerebral Blood Flow in the Parietal Regions in Patients With Schizophrenia With Impaired Insight

Author

Song, Jianmeng, primary, Kim, Julia, additional, Chavez, Sofia, additional, Caravaggio, Fernando, additional, Iwata, Yusuke, additional, Ueno, Fumihiko, additional, De Luca, Vincenzo, additional, Blumberger, Daniel M., additional, Remington, Gary, additional, Pollock, Bruce, additional, Graff-Guerrero, Ariel, additional, and Gerretsen, Philip, additional

Published
2021
Full Text
View/download PDF

172. GWAS Analysis of Insight in Schizophrenia

Author

Adanty, Christopher, primary, Kim, Julia, additional, Shrestha, Gopal, additional, Bani-Fatemi, Ali, additional, Remington, Gary, additional, Graff-Guerrero, Ariel, additional, Gerretsen, Philip, additional, and De Luca, Vincenzo, additional

Published
2021
Full Text
View/download PDF

173. Cortical Thickness in Patients With Schizophrenia With Impaired Insight Into Illness

Author

Kim, Julia, primary, Kambari, Yasaman, additional, Plitman, Eric, additional, Shah, Parita, additional, Iwata, Yusuke, additional, Caravaggio, Fernando, additional, Brown, Eric, additional, Nakajima, Shinichiro, additional, Chakravarty, M. Mallar, additional, De Luca, Vincenzo, additional, Remington, Gary, additional, Graff-Guerrero, Ariel, additional, Gerretsen, Philip, additional, and Song, Jianmeng, additional

Published
2021
Full Text
View/download PDF

178. Theta Phase-Gamma Amplitude Coupling During Working Memory and its Relationships With Demographic, Clinical, Genetic, Neurochemical, and Neurostructural Measures in Older Adults at Risk for Dementia

Author

Patterson, Rachel, primary, Brooks, Heather, additional, Mirjalili, Mina, additional, Rashidi-Ranjbar, Neda, additional, Zomorrodi, Reza, additional, Blumberger, Daniel M., additional, Kumar, Sanjeev, additional, Fischer, Corinne E., additional, Flint, Alastair J., additional, Graff-Guerrero, Ariel, additional, Herrmann, Nathan, additional, Kennedy, James L., additional, Lanctot, Krista L., additional, Mah, Linda, additional, Mulsant, Benoit H., additional, Pollock, Bruce G., additional, Voineskos, Aristotle N., additional, and Rajji, Tarek K., additional

Published
2021
Full Text
View/download PDF

180. Apathy is not associated with reduced ventral striatal volume in patients with schizophrenia

Author

Burrer, Achim; https://orcid.org/0000-0003-2012-5655, Caravaggio, Fernando; https://orcid.org/0000-0002-9048-4963, Manoliu, Andrei, Plitman, Eric, Gütter, Karoline, Habermeyer, Benedikt, Stämpfli, Philipp, Abivardi, Aslan; https://orcid.org/0000-0003-3946-7057, Schmidt, André; https://orcid.org/0000-0001-6055-8397, Borgwardt, Stefan, Chakravarty, Mallar, Lepage, Martin; https://orcid.org/0000-0003-4345-6502, Dagher, Alain, Graff-Guerrero, Ariel, Seifritz, Erich, Kaiser, Stefan, Kirschner, Matthias; https://orcid.org/0000-0002-9486-1439, Burrer, Achim; https://orcid.org/0000-0003-2012-5655, Caravaggio, Fernando; https://orcid.org/0000-0002-9048-4963, Manoliu, Andrei, Plitman, Eric, Gütter, Karoline, Habermeyer, Benedikt, Stämpfli, Philipp, Abivardi, Aslan; https://orcid.org/0000-0003-3946-7057, Schmidt, André; https://orcid.org/0000-0001-6055-8397, Borgwardt, Stefan, Chakravarty, Mallar, Lepage, Martin; https://orcid.org/0000-0003-4345-6502, Dagher, Alain, Graff-Guerrero, Ariel, Seifritz, Erich, Kaiser, Stefan, and Kirschner, Matthias; https://orcid.org/0000-0002-9486-1439

Abstract

Background: A growing body of neuroimaging research has revealed a relationship between blunted activation of the ventral striatum (VS) and apathy in schizophrenia. In contrast, the association between reduced striatal volume and apathy is less well established, while the relationship between VS function and structure in patients with schizophrenia remains an open question. Here, we aimed to replicate previous structural findings in a larger independent sample and to investigate the relationship between VS hypoactivation and VS volume. Methods: We included brain structural magnetic resonance imaging (MRI) data from 60 patients with schizophrenia (SZ) that had shown an association of VS hypoactivation with apathy during reward anticipation and 58 healthy controls (HC). To improve replicability, we applied analytical methods employed in two previously published studies: Voxel-based morphometry and the Multiple Automatically Generated Templates (MAGeT) algorithm. VS and dorsal striatum (DS) volume were correlated with apathy correcting for age, gender and total brain volume. Additionally, left VS activity was correlated with left VS volume. Results: We failed to replicate the association between apathy and reduced VS volume and did not find a correlation with DS volume. Functional and structural left VS measures exhibited a trend-level correlation (rs = 0.248, p = 0.067, r2 = 0.06). Conclusions: Our present data suggests that functional and structural striatal neuroimaging correlates of apathy can occur independently. Replication of previous findings may have been limited by other factors (medication, illness duration, age) potentially related to striatal volume changes in SZ. Finally, associations between reward-related VS function and structure should be further explored.

Published
2020

181. Understanding the Link Between Neuropsychiatric Symptoms and Cognitive Decline: Insights From Neuroimaging

Author

Rabheru, Kiran, Cassidy, Beverley, Gobessi, Linda, Mah, Linda, Lancot, Krista, Fischer, Corinne, Graff, Ariel, Brown, Eric, Chung, Jun Ku, Plitman, Eric, Caravaggio, Fernando, Iwata, Yusuke, Kim, Julia, Chakravarty, M. Mallar, Gerretsen, Philip, Graff-Guerrero, Ariel, Lanctôt, Krista, White-Campbell, Marilyn, Purcell, Bonnie, Powell, Simone, Conn, David, Van Bussel, Lisa, Simpson, Sandy, Dham, Pallavi, Warner, Michele, Andrew, Melissa H., Hussain, Maria, Egan, Rylan, Beesley, Theresa, Asmer, M. Selim, Baxter, Julia, Lewis, Maxine, Lam, David, Blumberger, Daniel, Kaster, Tyler, Noda, Yoshihiro, Knyahnytska, Yuliya, Downar, Jonathan, Rajji, Tarek K., Mulsant, Benoit H., Daskalakis, Zafiris J., Blackburn, Paul, Cassidy, Keri-Leigh, Rapoport, Mark, Kirkham, Julia, Baillod, Alanna, Dosanjh, Robbie, Ettie, Suzanne, Thoo, Vanessa, Dalley, Sara, Lazaro, Carole, Canfield, Amanda, Rajji, Tarek, Goodman, Michelle, Herrmann, Nathan, Pollock, Bruce G., Knezevic, Aliya Ali Dunja, Verhoef, Paul, Flint, Alastair, Saperson, Karen, Bosma, Mark, Andrew, Melissa, Abdool, Petal, Golas, Angela, Fischer, Corinne E., Chaudhari, Sumit, Sethi, Rickinder, Cheng, Catherine, Sokoloff, Lisa, Grief, Cindy J., Kumar, Sanjeev, Pollock, Bruce, Isserles, Moshe, Madan, Robert, Iaboni, Andrea, Martin, Lori Schindel, Newman, Kristine, Colborne, Debbie Hewitt, Fresco, Fernanda, Hamilton, Pam, Barel, Adriana, DeMattia, Lina, Domenic, Tricia, Judd, Teresa, Marshall, Cecelia, McKinnon, Jane, Quesnelle, Lisa, Schlegel, Kimberly, Tsokas, Mario, Woodman, Mary, Shulman, Richard, Waligora, Denise, Burhan, Amer M., Vasudev, Akshya, O’Regan, Tony, Forchuk, Cheryl, Waisman, Zohar, Holley, Joanna, Katchaluba, Janet, Waxman, Robin, Waxman, Robyn, Selvadurai, Melanie, Kates, Nick, Coleman, Sarah, Schwartz, Kenneth, Sham, Rosalind, Gardner, Sandra, Rej, Soham, Thomas, Zoe, Potes, Angela, Novak, Marta, Torres Platas, Susanna G., Gautier, Maryse, Segal, Marilyn, Looper, Karl, Lipman, Marc, Selchen, Stephen, Musci, Itsvan, Hennessy, Anne, Sage, Julia, Uy, Danielle, Saha, Parita, Mamo, David C., Voineskos, Aristotle N., Macri, Jennifer, Seitz, Dallas, Tau, Michael, Heisel, Marnin, Moore, Sharon L., Norman, Ross M.G., Links, Paul S., Flett, Gordon L., Sarma, Sisira, Eynan, Rahel, O’Rourke, Norm, Abraham, Eleenor, Wilchesky, Machelle, Voyer, Philippe, McCusker, Jane, Champoux, Nathalie, Monette, Johanne, Belzile, Eric, Vu, Minh, Lungu, Ovidiu, Bani-Fatemi, Ali, De Luca, Vincenzo, Bergeron, Claude, Letourneau, Geneviève, Escobar, Sophia, Turecki, Gustavo, Richard-Devantoy, Stéphane, Bhandari, Apoorva, Zomorrodi, Reza, Blumberger, Daniel M., Bogie, Bryce J. M., Lizius, Anne, Harms, Sheila, McConnell, Meghan M., Cajucom, Juan Miguel, Akiat, Danica Lou T., Corrales, Melissa A., de la Paz, Jon Martin O., Sy, Anne Janelle R., Zhang, Eljine Mae T., Rifareal, Joan Mae Perez T., Cheam, Amay, Elie, Dominique, Ghazala, Zaid, Tsoutsoulas, Christopher, Kern, Robert S., Banerjee, Joydip, Desai, Rita, Bowie, Christopher R., Harduwar, Rhea, Gambino, Sara, Baranchuk, Adrian, Haq, Farzana, Cuperfain, Ari, Chium, Karen, Chiu, Karen, Keller, Evelyn, Rousseau, François, Azouaou, Nassima, Jarboui, Manel, Telleria, Loraine, Simard, Alexandra, Morel, Lucie, Mérette, Chantale, Labbé, Annie, De Arco, Rossana Peredo Nunez, Knezevic, Dunja, Ali, Aliya, Szabuniewicz, Claudia, Verhoeff, Nicolaas Paul L.G, Flint, Alastair J., Voineskos, Aristotle, Bruneau, Marie-Andrée, Landreville, Philippe, Peretti, Matteo, Karanofksy, Mark, Salsberg, Jonathan, Pierre, Brandon, Melichercik, Ashley, Wilding, Laura, Hula, Vera, Neil-McKenzie, Margaret, Sebahana, Nadine, Waggott, Melissa, Kozar, Joseph, Sarraj, Mohamed, Sherman, Chelsea, Soffer, Matan, Grief, Cindy, Conn, David K., Gutmanis, Iris, Marlatt, Nicole, Minkovich, Michelle, Mikail, Maria, Lim, Lew, Kitamura, Christopher, de Lara, Catalina Lopez, Loheswaran, Genane, Saltmarche, Anita E., Ho, Kai Fai, Rajeh, Adnan, Amanullah, Shabbir, Elfakhani, Mohamad, Saltmarche, Anita, Naeser, Margaret A., Hamblin, Michael R., Perez-Parada, Jorge, McCahill, John, St. Denis, E.E., Hussain, M., Andrew, M., and O’Neill, Ryan

Subjects
Abstracts
Published
2018

183. Measuring amphetamine‐induced dopamine release in humans: A comparative meta‐analysis of [ 11 C]‐raclopride and [ 11 C]‐(+)‐PHNO studies

Author

Caravaggio, Fernando, primary, Porco, Natasha, additional, Kim, Julia, additional, Torres‐Carmona, Edgardo, additional, Brown, Eric, additional, Iwata, Yusuke, additional, Nakajima, Shinichiro, additional, Gerretsen, Philip, additional, Remington, Gary, additional, and Graff‐Guerrero, Ariel, additional

Published
2021
Full Text
View/download PDF

184. Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia

Author

Itahashi, Takashi, primary, Noda, Yoshihiro, additional, Iwata, Yusuke, additional, Tarumi, Ryosuke, additional, Tsugawa, Sakiko, additional, Plitman, Eric, additional, Honda, Shiori, additional, Caravaggio, Fernando, additional, Kim, Julia, additional, Matsushita, Karin, additional, Gerretsen, Philip, additional, Uchida, Hiroyuki, additional, Remington, Gary, additional, Mimura, Masaru, additional, Aoki, Yuta Y., additional, Graff-Guerrero, Ariel, additional, and Nakajima, Shinichiro, additional

Published
2021
Full Text
View/download PDF

185. Glutathione Levels and Glutathione-Glutamate Correlation in Patients With Treatment-Resistant Schizophrenia

Author

Iwata, Yusuke, primary, Nakajima, Shinichiro, additional, Plitman, Eric, additional, Truong, Peter, additional, Bani-Fatemi, Ali, additional, Caravaggio, Fernando, additional, Kim, Julia, additional, Shah, Parita, additional, Mar, Wanna, additional, Chavez, Sofia, additional, Remington, Gary, additional, Gerretsen, Philip, additional, De Luca, Vincenzo, additional, Sailasuta, Napapon, additional, and Graff-Guerrero, Ariel, additional

Published
2021
Full Text
View/download PDF

187. Alcohol Use Awareness and Insight Scale

Author

Kim, Julia, primary, Taggar, Anmol, additional, Quilty, Lena C., additional, Selby, Peter, additional, Caravaggio, Fernando, additional, Ueno, Fumihiko, additional, Song, Jianmeng, additional, Pollock, Bruce G., additional, Graff-Guerrero, Ariel, additional, and Gerretsen, Philip, additional

Published
2021
Full Text
View/download PDF

189. Exploring Patterns of Disturbed Eating in Psychosis: A Scoping Review

Author

Stogios, Nicolette, primary, Smith, Emily, additional, Asgariroozbehani, Roshanak, additional, Hamel, Laurie, additional, Gdanski, Alexander, additional, Selby, Peter, additional, Sockalingam, Sanjeev, additional, Graff-Guerrero, Ariel, additional, Taylor, Valerie, additional, Agarwal, Sri, additional, and Hahn, Margaret, additional

Published
2020
Full Text
View/download PDF

195. A Measure of Illness Awareness in Individuals With Nicotine Dependence-Nicotine Use Awareness and Insight Scale.

Author

Kim, Julia, Kambari, Yasaman, Taggar, Anmol, Quilty, Lena C, Selby, Peter, Caravaggio, Fernando, Ueno, Fumihiko, Song, Jianmeng, Pollock, Bruce G, Graff-Guerrero, Ariel, and Gerretsen, Philip

Subjects
NICOTINE addiction, NICOTINE, EXPLORATORY factor analysis, PSYCHOMETRICS, CRONBACH'S alpha, SUBSTANCE abuse treatment, SUBSTANCE abuse diagnosis, RESEARCH, RESEARCH evaluation, RESEARCH methodology, EVALUATION research, COMPARATIVE studies, RESEARCH funding
Abstract

Introduction: Impaired illness awareness or the inability to recognize that one has a dependence on nicotine may be a major barrier to seeking cessation treatment. To better understand the role of impaired illness awareness on treatment-seeking behavior and clinical outcomes, we developed and examined the psychometric properties of a novel scale measuring illness awareness in individuals with dependence on nicotine.Aims and Methods: We developed the Nicotine Use Awareness and Insight Scale (NAS), a 7-item self-report measure to assess the theoretical construct of illness awareness in individuals with dependence on nicotine (www.illnessawarenessscales.com). Data from participants 18 years of age or older were collected via a web-based survey company, Dynata. Participants with moderate dependence on nicotine were included, defined by a score of four or more on the Fagerström Test for Cigarette Dependence (FTCD) or the FTCD adapted for electronic cigarettes (eFTCD).Results: A total of 100 participants (mean [SD] age = 49.1 [16.1] years, 52% women) that met the inclusion criteria for either FTCD (n = 50) or eFTCD (n = 50) were included. The NAS demonstrated good convergent (r = .74, p < .001) and discriminant validity (r = .03, p = .786). It also demonstrated good internal consistency (Cronbach's alpha = 0.78) and one-month test-retest reliability (intra-class correlation = 0.86). An exploratory factor analysis yielded the retention of two components.Conclusions: The NAS is a novel scale to asses illness awareness in individuals with dependence on nicotine. This study provides initial support for the psychometric validity and reliability of NAS.Implications: The NAS may be used in research and clinical practice to evaluate the impact of impaired illness awareness on treatment-seeking behavior and clinical outcomes. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

196. The Rationale and Design of Behavioral Interventions for Management of Agitation in Dementia in a Multi-Site Clinical Trial.

Author

Zarei, Shadi, Colman, Sarah, Rostas, Aviva, Burhan, Amer M., Chu, Li, Davies, Simon JC, Derkach, Peter, Elmi, Sarah, Hussain, Maria, Gerretsen, Philip, Graff-Guerrero, Ariel, Ismail, Zahinoor, Kim, Donna, Krisman, Linda, Moghabghab, Rola, Mulsant, Benoit H., Nair, Vasavan, Pollock, Bruce G., Rej, Soham, and Simmons, Jyll

Abstract

Background: Agitation and aggression are common in patients with Alzheimer's disease and related dementias and pose a significant burden on patients, caregivers, and the healthcare systems. Guidelines recommend personalized behavioral interventions as the first-line treatment; however, these interventions are often underutilized. The Standardizing Care for Neuropsychiatric Symptoms and Quality of Life in Dementia (StaN) study (ClinicalTrials.gov Identifier # NCT0367220) is a multisite randomized controlled trial comparing an Integrated Care Pathway, that includes a sequential pharmacological algorithm and structured behavioral interventions, with treatment-as-usual to treat agitation in dementia in long-term care and inpatient settings.Objective: To describe the rationale and design of structured behavioral interventions in the StaN study.Methods: Structured behavioral interventions are designed and implemented based on the following considerations: 1) personalization, 2) evidence base, 3) dose and duration, 4) measurement-based care, and 5) environmental factors and feasibility.Results: The process to design behavioral interventions for each individual starts with a comprehensive assessment, followed by personalized, evidence-based interventions delivered in a standardized manner with ongoing monitoring of global clinical status. Measurement-based care is used to tailor the interventions and integrate them with pharmacotherapy.Conclusion: Individualized behavioral interventions in patients with dementia may be challenging to design and implement. Here we describe a process to design and implement individualized and structured behavioral interventions in the context of a multisite trial in long-term care and inpatient settings. This process can inform the design of behavioral interventions in future trials and in clinical settings for the treatment of agitation in dementia. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

200. Metformin for Early Onset Comorbid Type 2 Diabetes or Prediabetes in Schizophrenia Spectrum Disorders: A Double-Blind Randomized Pilot Study

Author

Hahn, Margaret, primary, Agarwal, Sri Mahavir, additional, Costa-Dookhan, Kenya, additional, Roshni, Panda, additional, Nicole, MacKenzie, additional, Cauccio-Treen, Quinn, additional, Caravaggio, Fernando, additional, Hashim, Eyesha, additional, Kirpalani, Anish, additional, Chintoh, Araba, additional, Kramer, Caroline, additional, Voineskos, Aristotle, additional, Graff-Guerrero, Ariel, additional, and Remington, Gary, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results